Kezar Life Sciences, Inc. (NASDAQ:KZR – Get Free Report) was the target of a significant drop in short interest in February. As of February 28th, there was short interest totalling 47,000 shares, a drop of 61.0% from the February 13th total of 120,600 shares. Based on an average daily trading volume, of 36,700 shares, the days-to-cover ratio is currently 1.3 days. Currently, 0.8% of the shares of the stock are sold short.
Analyst Upgrades and Downgrades
Several analysts have issued reports on the stock. Wells Fargo & Company reduced their price target on shares of Kezar Life Sciences from $11.00 to $9.00 and set an “equal weight” rating on the stock in a report on Thursday, December 19th. HC Wainwright reaffirmed a “neutral” rating on shares of Kezar Life Sciences in a research note on Monday, December 2nd. Finally, William Blair reissued an “outperform” rating on shares of Kezar Life Sciences in a research report on Friday, February 28th.
Check Out Our Latest Stock Report on KZR
Institutional Trading of Kezar Life Sciences
Kezar Life Sciences Trading Up 0.7 %
Shares of NASDAQ:KZR traded up $0.04 during trading on Friday, reaching $5.87. The stock had a trading volume of 4,143 shares, compared to its average volume of 65,187. The company has a quick ratio of 7.65, a current ratio of 7.65 and a debt-to-equity ratio of 0.05. The stock has a market cap of $42.83 million, a P/E ratio of -0.45 and a beta of 0.49. The business has a fifty day moving average price of $6.17 and a 200-day moving average price of $6.70. Kezar Life Sciences has a fifty-two week low of $5.20 and a fifty-two week high of $10.40.
About Kezar Life Sciences
Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.
Read More
- Five stocks we like better than Kezar Life Sciences
- How to Profit From Value Investing
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- What is Short Interest? How to Use It
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.